Maxwell Oluwole Akanbi, MD, PhD, on Lung Cancer: The Effect of Screening on the Incidence of Advanced Disease
2022 ASCO Annual Meeting
Maxwell Oluwole Akanbi, MD, PhD, of McLaren Regional Medical Center, discusses the study he conducted, using the SEER database, to evaluate the impact of lung cancer screening recommendations on low-dose CT scanning. The data suggest that guidelines from the U.S. Preventive Services Task Force led to a more rapid decline in the incidence of advanced disease in the United States, especially among minority populations (Abstract 10506).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Lung cancer is the leading cause of cancer mortality in the US, and this is because most patients with lung cancer are diagnosed at advanced stages of the disease. Trying to make patients present earlier has been an elusive challenge, until in 2011, when results of the National Lung Cancer Trial were reported. This study showed that low-dose CT scan could improve survival in patients with lung cancer by making earlier diagnosis. Although this has been shown in clinical trials, the government has ruled out lung cancer screening in the general population without also actually knowing whether it is efficacious in the general population.
Our study was to evaluate the effectiveness of lung cancer screening in the US general population. You will use the SEER database, we analyzed data of patient diagnosed with lung cancer from 2004 to 2018. Our goal was to see if the incidence of advanced lung cancer reduced over this time. Our results showed that incidence of advanced lung cancer actually decreased in the US population following the rollout of lung cancer screening. This was particularly significant in minority populations. This is encouraging because there have been concerns that lung cancer screening may not be very effective in this population because they had limited access to screening facilities.
So, while this is encouraging, the work is not yet done. Our end goal is to make sure there's reduction in lung cancer mortality. There are still barriers between screening and mortality, so the next stage of our study will be to see whether this reduction in incidence of advanced lung cancer actually translate to reduction in lung cancer mortality.
The ASCO Post Staff
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Ignace Vergote, MD, PhD, of Belgium’s University Hospitals Leuven, discuss interim safety and efficacy results from a third dose-expansion cohort evaluating first-line tisotumab vedotin-tftv plus pembrolizumab in patients with recurrent or metastatic cervical cancer. Data on the combination showed durable antitumor activity with a manageable safety profile (Abstract 5507).
The ASCO Post Staff
Courtney D. DiNardo, MD, MSCE, of The University of Texas MD Anderson Cancer Center, and Jorge E. Cortes, MD, of Georgia Cancer Center at Augusta University, discuss phase III results from the ASCEMBL trial, which showed that after more than 2 years of follow-up, asciminib continued to yield superior efficacy and better safety and tolerability vs bosutinib in patients with chronic myeloid leukemia (CML) in chronic phase. These results continue to support the use of this kinase inhibitor as a new CML therapy, says Dr. Cortes, with the potential to transform the standard of care (Abstract 7004).
The ASCO Post Staff
Stephanie Walker, a former nurse and current activist with the Metastatic Breast Cancer Alliance, discusses findings from the BECOME project (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement). They show that, even though Black patients comprise between 4% and 6% of all clinical trial participants, Black women with metastatic breast cancer are willing to consider taking part if steps were taken to increase their awareness, build trust through clear communication with health-care providers, involve people of shared racial/ethnic identity and health experience, and help patients find and access trials (Abstract 1014).
The ASCO Post Staff
Apar Kishor Ganti, MD, of the University of Nebraska Medical Center, discusses results from the CALGB 30610 study, which showed a similar clinical benefit for once- and twice-daily radiotherapy administered to patients with limited-stage small cell lung cancer. While both regimens were well tolerated, patients who received radiotherapy once daily had better quality-of-life scores at week 3 and slightly worse scores at week 12. Patients believed the once-daily regimen was more convenient (Abstract 8504).
The ASCO Post Staff
Carryn M. Anderson, MD, of the University of Iowa Hospital, discusses phase III results of the ROMAN trial of avasopasem manganese for patients with severe oral mucositis who are receiving chemoradiotherapy for locally advanced, nonmetastatic head and neck cancer. Compared with placebo, avasopasem manganese improved severe oral mucositis (Abstract 6005).
